The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Comparing haploidentical SCT with PTCy to matched unrelated donor transplant for AML in CR2
Yishan Ye, MD, PhD, Zhejiang University, Hangzhou, China, discusses a study comparing haploidentical stem cell transplantation (SCT) with post-transplant cyclophosphamide (PTCy) to matched unrelated donor (MUD) transplant in patients with acute myeloid leukemia (AML) in second complete remission (CR2). Dr Ye highlights that haploidentical transplant with PTCy resulted in superior graft-versus-host disease (GvHD)-free, relapse-free survival (GRFS), with reduced relapse rate and chronic GvHD incidence. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Donor selection is very important and we need to make the best choice for the patient. So in the PTCy situation, we wanted to compare the PTCy haploidentical and matched sibling and matched unrelated in this EBMT registry-based study, including 200 centers and more than 3,000 patients. So in this study, we find that haploidentical transplant indeed brought about a better GHD-free, relapse-free survival (GRFS) as compared to matched sibling donors with PTCy prophylaxis, which brought about a reduced relapse incidence and a reduced chronic GvHD incidence...
Donor selection is very important and we need to make the best choice for the patient. So in the PTCy situation, we wanted to compare the PTCy haploidentical and matched sibling and matched unrelated in this EBMT registry-based study, including 200 centers and more than 3,000 patients. So in this study, we find that haploidentical transplant indeed brought about a better GHD-free, relapse-free survival (GRFS) as compared to matched sibling donors with PTCy prophylaxis, which brought about a reduced relapse incidence and a reduced chronic GvHD incidence. So I think we can make haplo a very good alternative to matched sibling donor. And also we can see more opportunities to improve our donor selection in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
